Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Schedule of company recognized stock compensation expense

For the three and nine months ended September 30, 2023 and 2022, the Company recognized share-based compensation expense as follows:

	Three months ended September 30,					Nine months ended September 30,
	2023			2022		2023			2022
Cost of services	$	(442	)	$	—	$	(442	)	$	11,101
Research and development		(159,742	)		82,659		(41,914	)		223,638
General and administrative		74,411			108,672		259,452			387,992
Sales and marketing		(143,710	)		37,036		(78,928	)		104,658
	$	(229,483	)	$	228,367	$	138,168		$	727,389

Schedule of outstanding warrants to purchase shares of common stock

At September 30, 2023 and December 31, 2022, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance		Exercise Price	Expiration	September 30, 2023 (1)	December 31, 2022 (1)
February 2015	$	66,000.00	February 2025	23	23
February 2018	$	1,625.00	February 2023	—	462
February 2018	$	1,300.00	February 2023	—	3,848
October 2019	$	40.00	October 2024	17,700	17,700
October 2019	$	52.00	October 2024	11,750	11,750
November 2020	$	50.44	May 2026	12,107	12,107
February 2021	$	78.00	August 2026	20,834	20,834
October 2022	$	7.54	April 2028	—	1,224,489
May 2023	$	0.7785	(2)	10,892,728	—
				10,955,142	1,291,213

(1) Warrants to purchase fractional shares of common stock resulting from the reverse stock splits effected on August 22, 2019 and January 5, 2023 were rounded up to the next whole share of common stock on a holder by holder basis.

(2) Warrants will be exercisable beginning on the date of stockholder approval of the exercisability of the warrants under Nasdaq rules or, pursuant to the Warrant Inducement Agreement entered into on October 12, 2023, as amended on October 26, 2023 (the “Inducement Agreement”), upon the payment of additional consideration of $0.25 per share of common stock issued upon exercise of any existing warrants. The warrants not exercised as part of the Inducement Agreement will expire on the five-year anniversary of the date of such stockholder approval (see Note 11).